XML 26 R14.htm IDEA: XBRL DOCUMENT
v3.25.1

Fair Value of Financial Instruments | 3 Months Ended
--- | ---
Mar. 31, 2025
Fair Value Disclosures [Abstract] |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company values financial instruments in accordance with ASC 820, using the techniques and approaches outlined in the Company's valuation guidelines, which are approved by the Board. During the periods ended March 31, 2025 and December 31, 2024, there were no changes to the Company’s valuation techniques or approaches as described herein. Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2025 and December 31, 2024.
(in thousands) |  | Balance as of March 31, 2025 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Description |  |  |  |
Cash and cash equivalents |  |  |  |  |  |  |  |
Money Market Fund(1) |  | $ | 26,000 |  |  | $ | 26,000 |  |  | $ | — |  |  | $ | — |
Other assets and liabilities |  |  |  |  |  |  |  |
Escrow and Other Investment Receivables |  | $ | 1,966 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,966 |
Accounts Payable and Accrued Liabilities |  | (972) |  |  | — |  |  | — |  |  | (972) |
Investments |  |  |  |  |  |  |  |
Senior Secured Debt |  | $ | 3,674,498 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,674,498 |
Unsecured Debt |  | 64,736 |  |  | — |  |  | — |  |  | 64,736 |
Preferred Stock |  | 52,662 |  |  | — |  |  | — |  |  | 52,662 |
Common Stock(2) |  | 94,088 |  |  | 35,194 |  |  | — |  |  | 58,894 |
Warrants |  | 31,473 |  |  | — |  |  | 10,888 |  |  | 20,585 |
|  | $ | 3,917,457 |  |  | $ | 35,194 |  |  | $ | 10,888 |  |  | $ | 3,871,375 |
Investment Funds & Vehicles measured at Net Asset Value(3) |  | 6,993 |  |  |  |  |  |  |
Total Investments, at fair value |  | $ | 3,924,450 |  |  |  |  |  |  |
Derivative Instruments(4) |  | (301) |  |  |  |  |  |  |
Total Investments including cash and cash equivalents and derivative instruments |  | $ | 3,950,149 |  |  |  |  |  |  |
(in thousands) |  | Balance as of December 31, 2024 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Description |  |  |  |
Cash and cash equivalents |  |  |  |  |  |  |  |
Money Market Fund(1) |  | $ | 21,100 |  |  | $ | 21,100 |  |  | $ | — |  |  | $ | — |
Other assets and liabilities |  |  |  |  |  |  |  |
Escrow and Other Investment Receivables |  | $ | 152 |  |  | $ | — |  |  | $ | — |  |  | $ | 152 |
Accounts Payable and Accrued Liabilities |  | (1,012) |  |  | $ | — |  |  | $ | — |  |  | (1,012) |
Investments |  |  |  |  |  |  |  |
Senior Secured Debt |  | $ | 3,419,044 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,419,044 |
Unsecured Debt |  | 75,557 |  |  | — |  |  | — |  |  | 75,557 |
Preferred Stock |  | 53,802 |  |  | — |  |  | — |  |  | 53,802 |
Common Stock(2) |  | 74,855 |  |  | 30,262 |  |  | — |  |  | 44,593 |
Warrants |  | 30,500 |  |  | — |  |  | 8,677 |  |  | 21,823 |
|  | $ | 3,653,758 |  |  | $ | 30,262 |  |  | $ | 8,677 |  |  | $ | 3,614,819 |
Investment Funds & Vehicles measured at Net Asset Value(3) |  | 6,220 |  |  |  |  |  |  |
Total Investments, at fair value |  | $ | 3,659,978 |  |  |  |  |  |  |
Derivative Instruments(4) |  | 538 |  |  |  |  |  |  |
Total Investments including cash and cash equivalents and derivative instruments |  | $ | 3,681,616 |  |  |  |  |  |  |
(1)This investment is included in Cash and cash equivalents in the accompanying Consolidated Statements of Assets and Liabilities. (2)Common stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's common stock. (3)In accordance with U.S. GAAP, certain investments are measured at fair value using the NAV per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statements of Assets and Liabilities. (4)Derivative Instruments are carried at fair value and are a Level 2 security within the Company's fair value hierarchy. The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the three months ended March 31, 2025 and 2024.
(in thousands) | Balance as of January 1, 2025 |  | Net Realized Gains (Losses)(1) |  | Net Change in Unrealized Appreciation (Depreciation)(2) |  | Purchases(5) |  | Sales |  | Repayments(6) |  | Gross Transfers into Level 3(3)* |  | Gross Transfers out of Level 3(3)* |  | Balance as of March 31, 2025
Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Senior Secured Debt | $ | 3,419,044 |  |  | $ | (48) |  |  | $ | (25,181) |  |  | $ | 428,830 |  |  | $ | — |  |  | $ | (148,147) |  |  | $ | — |  |  | $ | — |  |  | $ | 3,674,498 |
Unsecured Debt | 75,557 |  |  | — |  |  | 65 |  |  | 1,336 |  |  | — |  |  | — |  |  | — |  |  | (12,222) |  |  | 64,736 |
Preferred Stock | 53,802 |  |  | — |  |  | (3,953) |  |  | 2,813 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 52,662 |
Common Stock | 44,593 |  |  | (670) |  |  | (2,014) |  |  | — |  |  | (331) |  |  | — |  |  | 17,316 |  |  | — |  |  | 58,894 |
Warrants | 21,823 |  |  | (63) |  |  | (1,527) |  |  | 352 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 20,585 |
Other Assets and Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow and Other Investment Receivables | 152 |  |  | 56 |  |  | — |  |  | 1,814 |  |  | (56) |  |  | — |  |  | — |  |  | — |  |  | 1,966 |
Accounts Payable and Accrued Liabilities | (1,012) |  |  | — |  |  | 358 |  |  | 44 |  |  | (362) |  |  | — |  |  | — |  |  | — |  |  | (972) |
Total | $ | 3,613,959 |  |  | $ | (725) |  |  | $ | (32,252) |  |  | $ | 435,189 |  |  | $ | (749) |  |  | $ | (148,147) |  |  | $ | 17,316 |  |  | $ | (12,222) |  |  | $ | 3,872,369 |
(in thousands) | Balance as of January 1, 2024 |  | Net Realized Gains (Losses)(1) |  | Net Change in Unrealized Appreciation (Depreciation)(2) |  | Purchases(5) |  | Sales |  | Repayments(6) |  | Gross Transfers into Level 3(4)* |  | Gross Transfers out of Level 3(4)* |  | Balance as of March 31, 2024
Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Senior Secured Debt | $ | 2,987,577 |  |  | $ | — |  |  | $ | (104) |  |  | $ | 498,787 |  |  | $ | — |  |  | $ | (174,035) |  |  | $ | — |  |  | $ | — |  |  | $ | 3,312,225 |
Unsecured Debt | 69,722 |  |  | — |  |  | 481 |  |  | 542 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 70,745 |
Preferred Stock | 53,038 |  |  | — |  |  | (2,326) |  |  | 1,597 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 52,309 |
Common Stock | 41,790 |  |  | — |  |  | (1,752) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 40,038 |
Warrants | 22,088 |  |  | 904 |  |  | (2,113) |  |  | 1,232 |  |  | (2,829) |  |  | — |  |  | — |  |  | — |  |  | 19,282 |
Other Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow and Other Investment Receivables | 10,888 |  |  | 13 |  |  | 7,353 |  |  | — |  |  | (13,234) |  |  | — |  |  | — |  |  | — |  |  | 5,020 |
Total | $ | 3,185,103 |  |  | $ | 917 |  |  | $ | 1,539 |  |  | $ | 502,158 |  |  | $ | (16,063) |  |  | $ | (174,035) |  |  | $ | — |  |  | $ | — |  |  | $ | 3,499,619 |
* The Company recognizes transfers as of the transaction date. (1)Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. (2)Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations. (3)Transfers out of Level 3 during the three months ended March 31, 2025 related to the conversion of the Company's Level 3 debt investments in Hercules Adviser LLC and Carbon Health Technologies, Inc., into common stock Level 3 investments. Transfers into Level 3 during the three months ended March 31, 2025 included the conversion of 23andMe, Inc. Level 1 common stock into Level 3 common stock due to bankruptcy and delisting. (4)There were no transfers into or out of Level 3 during the three months ended March 31, 2024. (5)Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of Level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. (6)Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization. The following table presents the net unrealized appreciation (depreciation) recorded for debt, preferred stock, common stock and warrant Level 3 investments relating to assets still held at the reporting date.
(in millions) | Three Months Ended March 31,
| 2025 |  | 2024
Debt investments | $ | (23.4) |  |  | $ | 0.4 |
Preferred stock | (4.0) |  |  | (2.3) |
Common stock | (2.3) |  |  | (1.8) |
Warrant investments | (1.6) |  |  | 0.7 |
The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of March 31, 2025 and December 31, 2024. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation guidelines, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.
Investment Type - Level 3 Debt Investments |  | Fair Value as of March 31, 2025 (in thousands) |  | Valuation Techniques/ Methodologies |  | Unobservable Input(1) |  | Range |  | Weighted Average(2)
Pharmaceuticals |  | $ | 787,506 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 8.78% - 16.34% |  | 12.90%
|  |  |  |  | Premium/(Discount) |  | (2.50%) - 3.00% |  | 0.17%
|  | 73,719 |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 10.00% - 90.00% |  | 80.32%
Technology |  | 1,281,565 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 9.81% - 21.18% |  | 13.21%
|  |  |  |  | Premium/(Discount) |  | (1.00%) - 5.00% |  | 0.17%
|  | 27,673 |  |  | Convertible Note Analysis |  | Probability weighting of alternative outcomes |  | 1.00% - 70.00% |  | 50.94%
|  | 53,584 |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 10.00% - 72.50% |  | 60.35%
Sustainable and Renewable Technology |  | 19,903 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 15.78% - 15.78% |  | 15.78%
|  |  |  |  | Premium/(Discount) |  | 0.50% - 0.50% |  | 0.50%
Medical Devices |  | 59,851 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 11.81% - 12.77% |  | 12.26%
|  |  |  |  |  | Premium/(Discount) |  | 0.00% - 0.50% |  | 0.26%
Lower Middle Market |  | 585,224 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 10.43% - 17.48% |  | 13.63%
|  |  |  |  | Premium/(Discount) |  | (0.75%) - 2.25% |  | 0.58%
Debt Investments for which Cost Approximates Fair Value
|  | 516,515 |  |  | Debt Investments originated within 6 months |  |  |  |
|  | 214,238 |  |  | Imminent Payoffs(4) |  |  |  |
|  | 82,666 |  |  | Debt Investments Maturing in Less than One Year |  |  |  |
|  | 36,790 |  |  | Debt Investments in Wholly-Owned Subsidiaries |  |  |  |
|  | $ | 3,739,234 |  |  | Total Level 3 Debt Investments |  |  |  |
Escrow and Other Investment Receivables |  | 1,966 |  |  | Expected Proceeds |  |  |  |  |  |
Accounts Payable and Accrued Liabilities |  | (972) |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 20.00% - 50.00% |  | 39.79%
|  | $ | 3,740,228 |  |  | Total Level Three Debt Investments and Other Investment Receivables (Payables)
(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: •Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. •Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, “Space Technologies”, and “Software” industries. •Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. •Medical Devices, above, is comprised of debt investments in the “Medical Devices & Equipment” industry. •Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2)The weighted averages are calculated based on the fair market value of each investment. (3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables (payables) is the probability weighting of alternative outcomes. (4)Imminent Payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.
Investment Type - Level 3 Debt Investments |  | Fair Value as of December 31, 2024 (in thousands) |  | Valuation Techniques/ Methodologies |  | Unobservable Input(1) |  | Range |  | Weighted Average(2)
Pharmaceuticals |  | $ | 947,065 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 8.42% - 16.19% |  | 12.03%
|  |  |  |  | Premium/(Discount) |  | (2.50%) - 3.00% |  | 0.13%
|  | 55,344 |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 20.00% - 80.00% |  | 75.53%
Technology |  | 1,365,943 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 10.21% - 20.58% |  | 13.10%
|  |  |  |  | Premium/(Discount) |  | (0.75%) - 4.50% |  | 0.20%
|  | 26,869 |  |  | Convertible Note Analysis |  | Probability weighting of alternative outcomes |  | 1.00% - 70.00% |  | 50.66%
|  | 51,004 |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 22.00% - 78.00% |  | 66.34%
Sustainable and Renewable Technology |  | 21,102 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 12.41% - 15.44% |  | 15.25%
|  |  |  |  |  | Premium/(Discount) |  | 0.25% - 3.50% |  | 0.45%
Medical Devices |  | 59,645 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 11.79% - 12.75% |  | 12.24%
|  |  |  |  | Premium/(Discount) |  | 0.00% - 0.50% |  | 0.26%
Lower Middle Market |  | 636,258 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 10.27% - 21.00% |  | 14.12%
|  |  |  |  |  | Premium/(Discount) |  | (0.25%) - 5.00% |  | 1.07%
Debt Investments for which Cost Approximates Fair Value
|  | 242,833 |  |  | Debt Investments originated within 6 months |  |  |  |
|  | 4,141 |  |  | Imminent Payoffs(4) |  |  |  |
|  | 36,185 |  |  | Debt Investments Maturing in Less than One Year
|  | 48,212 |  |  | Debt Investments in Wholly-Owned Subsidiaries |  |  |  |
|  | $ | 3,494,601 |  |  | Total Level 3 Debt Investments
Accounts Payable and Accrued Liabilities |  | (1,012) |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 20.00% - 50.00% |  | 38.44%
|  | $ | 3,493,589 |  |  | Total Level Three Debt Investments and Other Investment Receivables (Payables)
(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: •Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. •Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, and “Software” industries. •Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. •Medical Devices, above, is comprised of debt investments in the “Medical Devices & Equipment” industry. •Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2)The weighted averages are calculated based on the fair market value of each investment. (3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables (payables) is the probability weighting of alternative outcomes. (4)Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.
Investment Type - Level 3 Equity and Warrant Investments |  | Fair Value as of March 31, 2025 (in thousands) |  | Valuation Techniques/ Methodologies |  | Unobservable Input(1) |  | Range |  | Weighted Average(5)
Equity Investments |  | $ | 48,390 |  |  | Market Comparable Companies |  | Revenue Multiple(2) |  | 0.2x - 16.5x |  | 7.0x
|  |  |  |  | Tangible Book Value Multiple(2) |  | 1.6x - 1.6x |  | 1.6x
|  |  |  |  | Discount for Lack of Marketability(3) |  | 16.31% - 92.53% |  | 33.34%
|  | 7,237 |  |  | Market Adjusted OPM Backsolve |  | Market Equity Adjustment(4) |  | (97.68%) - (0.65%) |  | (30.32%)
|  | 50,151 |  |  | Discounted Cash Flow |  | Discount Rate(7) |  | 11.55% - 32.94% |  | 29.55%
|  | 5,778 |  |  | Other(6) |  |  |  |  |  |
Warrant Investments |  | 18,779 |  |  | Market Comparable Companies |  | Revenue Multiple(2) |  | 0.5x - 12.9x |  | 4.3x
|  |  |  |  | Discount for Lack of Marketability(3) |  | 7.36% - 32.40% |  | 24.28%
|  | 1,806 |  |  | Market Adjusted OPM Backsolve |  | Market Equity Adjustment(4) |  | (70.08%) - 54.33% |  | (3.87%)
Total Level 3 Equity and Warrant Investments |  | $ | 132,141 |  |  |  |  |  |  |  |  |
(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5)Weighted averages are calculated based on the fair market value of each investment. (6)The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. (7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
Investment Type - Level 3 Equity and Warrant Investments |  | Fair Value as of December 31, 2024 (in thousands) |  | Valuation Techniques/ Methodologies |  | Unobservable Input(1) |  | Range |  | Weighted Average(5)
Equity Investments |  | $ | 45,420 |  |  | Market Comparable Companies |  | Revenue Multiple(2) |  | 0.4x - 16.8x |  | 9.1x
|  |  |  |  | Tangible Book Value Multiple(2) |  | 1.7x - 1.7x |  | 1.7x
|  |  |  |  | Discount for Lack of Marketability(3) |  | 17.64% - 92.80% |  | 36.12%
|  | 12,374 |  |  | Market Adjusted OPM Backsolve |  | Market Equity Adjustment(4) |  | (96.57%) - 24.76% |  | (17.57%)
|  | 34,677 |  |  | Discounted Cash Flow |  | Discount Rate(7) |  | 12.17% - 33.34% |  | 30.21%
|  | 5,924 |  |  | Other(6) |  |  |  |  |  |
Warrant Investments |  | 18,302 |  |  | Market Comparable Companies |  | Revenue Multiple(2) |  | 0.8x - 14.1x |  | 4.5x
|  |  |  |  |  | Discount for Lack of Marketability(3) |  | 14.72% - 34.35% |  | 26.76%
|  | 3,521 |  |  | Market Adjusted OPM Backsolve |  | Market Equity Adjustment(4) |  | (56.36%) - 24.76% |  | 1.33%
Total Level 3 Equity and Warrant Investments |  | $ | 120,218 |  |  |  |  |  |  |  |  |
(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5)Weighted averages are calculated based on the fair market value of each investment. (6)The fair market value of these investments is derived based on recent market transactions. (7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt obligations of the Company are recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument. As of March 31, 2025 and December 31, 2024, the 2033 Notes (as defined in “Note 5 - Debt”) were trading on the New York Stock Exchange (“NYSE”) at $25.23 and $25.17 per unit at par value. The par value at underwriting for the 2033 Notes was $25.00 per unit. Based on market quotations on or around March 31, 2025 and December 31, 2024, the 2031 Asset-Backed Notes (as defined in “Note 5 - Debt”) were quoted for 0.971 and 0.963. Based on market quotations on or around March 31, 2025, the 2028 Convertible Notes (as defined in “Note 5 - Debt”) were quoted for 0.981 per dollar at par value. The fair values of the SBA debentures, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026, and January 2027 Notes (each as defined in “Note 5 - Debt”) are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms. The fair values of the outstanding debt under the MUFG Bank Facility and the SMBC Facility (each as defined in “Note 5 - Debt”) are equal to their outstanding principal balances as of March 31, 2025 and December 31, 2024. The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of March 31, 2025 and December 31, 2024:
(in thousands) |  | March 31, 2025
Description |  | Carrying Value |  | Approximate Fair Value |  | Identical Assets (Level 1) |  | Observable Inputs (Level 2) |  | Unobservable Inputs (Level 3)
SBA Debentures |  | $ | 287,049 |  |  | $ | 268,236 |  |  | $ | — |  |  | $ | — |  |  | $ | 268,236 |
June 2025 Notes |  | 69,960 |  |  | 70,637 |  |  | — |  |  | — |  |  | 70,637 |
June 2025 3-Year Notes |  | 49,965 |  |  | 50,678 |  |  | — |  |  | — |  |  | 50,678 |
March 2026 A Notes |  | 49,913 |  |  | 49,012 |  |  | — |  |  | — |  |  | 49,012 |
March 2026 B Notes |  | 49,905 |  |  | 49,036 |  |  | — |  |  | — |  |  | 49,036 |
September 2026 Notes |  | 323,566 |  |  | 305,377 |  |  | — |  |  | — |  |  | 305,377 |
January 2027 Notes |  | 347,598 |  |  | 330,404 |  |  | — |  |  | — |  |  | 330,404 |
2028 Convertible Notes |  | 278,503 |  |  | 282,109 |  |  | — |  |  | 282,109 |  |  | — |
2031 Asset-Backed Notes |  | 116,272 |  |  | 113,433 |  |  | — |  |  | 113,433 |  |  | — |
2033 Notes |  | 39,070 |  |  | 40,368 |  |  | — |  |  | 40,368 |  |  | — |
MUFG Bank Facility |  | 105,000 |  |  | 105,000 |  |  | — |  |  | — |  |  | 105,000 |
SMBC Facility |  | 259,822 |  |  | 260,006 |  |  | — |  |  | — |  |  | 260,006 |
Total |  | $ | 1,976,623 |  |  | $ | 1,924,296 |  |  | $ | — |  |  | $ | 435,910 |  |  | $ | 1,488,386 |
(in thousands) |  | December 31, 2024
Description |  | Carrying Value |  | Approximate Fair Value |  | Identical Assets (Level 1) |  | Observable Inputs (Level 2) |  | Unobservable Inputs (Level 3)
SBA Debentures |  | $ | 271,371 |  |  | $ | 260,436 |  |  | $ | — |  |  | $ | — |  |  | $ | 260,436 |
February 2025 Notes |  | 49,981 |  |  | 50,698 |  |  | — |  |  | — |  |  | 50,698 |
June 2025 Notes |  | 69,919 |  |  | 69,308 |  |  | — |  |  | — |  |  | 69,308 |
June 2025 3-Year Notes |  | 49,926 |  |  | 49,713 |  |  | — |  |  | — |  |  | 49,713 |
March 2026 A Notes |  | 49,889 |  |  | 49,052 |  |  | — |  |  | — |  |  | 49,052 |
March 2026 B Notes |  | 49,880 |  |  | 49,087 |  |  | — |  |  | — |  |  | 49,087 |
September 2026 Notes |  | 323,321 |  |  | 302,244 |  |  | — |  |  | — |  |  | 302,244 |
January 2027 Notes |  | 347,265 |  |  | 327,928 |  |  | — |  |  | — |  |  | 327,928 |
2031 Asset-Backed Notes |  | 118,769 |  |  | 115,031 |  |  | — |  |  | 115,031 |  |  | — |
2033 Notes |  | 39,043 |  |  | 40,272 |  |  | — |  |  | 40,272 |  |  | — |
MUFG Bank Facility |  | 116,000 |  |  | 116,000 |  |  | — |  |  | — |  |  | 116,000 |
SMBC Facility |  | 283,591 |  |  | 283,591 |  |  | — |  |  | — |  |  | 283,591 |
Total |  | $ | 1,768,955 |  |  | $ | 1,713,360 |  |  | $ | — |  |  | $ | 155,303 |  |  | $ | 1,558,057 |

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration